You are here

ANR funds our Coronavirus research

May 2020

Two of our research programs on the new coronavirus SARS-CoV-2, responsible for the disease COVID-19, have been selected following the ANR (Agence nationale de la recherche) Flash-COVID-19 call. These projects are both receiving an ANR funding of €200,000 to support our researchers in the fight against the SARS-CoV-2 epidemic.



TargEnt-COVID-19: A program targeting viral cell entry for COVID-19 control and cure

This project is led by Thomas Baumert, PU-PH, Director of the Institute of Viral and Liver Disease, the Inserm UMR_S1110 unit and the HepSYS LabEx.

Using our experience in the molecular and clinical investigation of virus cell entry and the discovery of viruses entry inhibitors. We aim to apply our well-established screening approaches, compounds, and expertise to unravel urgently needed targets and compounds for control of COVID-19. Using established coronavirus model systems, we will discover host factors for the coronavirus life cycle focusing on virus cell entry. Additionally, we will assess the antiviral activity of compounds targeting host factors of coronaviruses.

We anticipate that our program will unravel novel strategies and compounds for antiviral therapy for urgently needed control and cure of SARS-CoV-2 infection.

TerminAnion: Polyanion delivery and protection systems against viral infections

This project is led by Philippe Lavalle, Research Director (INSERM / University of Strasbourg, UMR_S 1121) in partnership with Catherine Schuster, Research Director at the Institute of Viral and Liver Disease and Engin Vrana, CEO and co-founder of the start-up Spartha Medical with Philippe Lavalle. They are working together to develop a solution to counter SARS-CoV-2 infection with specific anti-viral coatings solution.

The aim of TerminAnion is to propose an anti-viral protection system applicable to the surfaces of different medical devices and to people, particularly in hospitals, to limit virus transmission.


These new research programs enable our researchers to respond quickly to the COVID-19 outbreak to provide the resources to control and cure this new disease.